Literature DB >> 17485406

Function and regulation of the complement system in cardiovascular diseases.

Riina Oksjoki1, Petri T Kovanen, Seppo Meri, Markku O Pentikainen.   

Abstract

The complement system plays a central role in innate immunity and also regulates adaptive immunity. The complement system has been demonstrated to contribute to various diseases, including cardiovascular diseases. Complement is extensively activated in atherosclerotic lesions, in arterial aneurysms, and in the myocardium of ischemic and failing hearts. Accumulating evidence shows that limitation of excessive complement activation under these conditions may hold therapeutic value. On the other hand, defects in the classical complement pathway predispose to vasculitis and atherosclerosis, possibly due to ineffective clearance of apoptotic/necrotic cells and abnormal processing of immune complexes. Here, we describe complement activation and regulation in cardiovascular diseases and discuss the evidence derived mainly from experimental animals suggesting that modulation of complement activation may alter the course of these disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17485406     DOI: 10.2741/2419

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  24 in total

1.  Role of endothelial N-glycan mannose residues in monocyte recruitment during atherogenesis.

Authors:  David W Scott; Jie Chen; Balu K Chacko; James G Traylor; Anthony W Orr; Rakesh P Patel
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-06-21       Impact factor: 8.311

2.  C3 Polymorphism Influences Circulating Levels of C3, ASP and Lipids in Schizophrenic Patients.

Authors:  Mohamed Jalloul Nsaiba; Marc Lapointe; Hajer Mabrouk; Wahiba Douki; Lotfi Gaha; Louis Pérusse; Claude Bouchard; Besma Bel Hadj Jrad; Katherine Cianflone
Journal:  Neurochem Res       Date:  2015-02-27       Impact factor: 3.996

Review 3.  Mast cells in atherogenesis: actions and reactions.

Authors:  Petri T Kovanen
Journal:  Curr Atheroscler Rep       Date:  2009-05       Impact factor: 5.113

4.  Early decreased plasma levels of factor B and C5a are important biomarkers in children with Kawasaki disease.

Authors:  Qing-Mei Zou; Xiao-Hui Li; Rui-Xia Song; Nan-Ping Xu; Ting Zhang; Ming-Ming Zhang; Yao Lin; Lin Shi; Jin Fu; Xiao-Dai Cui
Journal:  Pediatr Res       Date:  2015-05-04       Impact factor: 3.756

Review 5.  CD46 in innate and adaptive immunity: an update.

Authors:  J Cardone; G Le Friec; C Kemper
Journal:  Clin Exp Immunol       Date:  2011-04-13       Impact factor: 4.330

6.  Complement C3a predicts outcome in cardiac resynchronization therapy of heart failure.

Authors:  Gábor Széplaki; András Mihály Boros; Szabolcs Szilágyi; István Osztheimer; Zsigmond Jenei; Annamária Kosztin; Klaudia Vivien Nagy; Júlia Karády; Levente Molnár; Tamás Tahin; Endre Zima; László Gellér; Zoltán Prohászka; Béla Merkely
Journal:  Inflamm Res       Date:  2016-08-04       Impact factor: 4.575

7.  Abundant lipid and protein components of drusen.

Authors:  Lan Wang; Mark E Clark; David K Crossman; Kyoko Kojima; Jeffrey D Messinger; James A Mobley; Christine A Curcio
Journal:  PLoS One       Date:  2010-04-23       Impact factor: 3.240

Review 8.  Aging, age-related macular degeneration, and the response-to-retention of apolipoprotein B-containing lipoproteins.

Authors:  Christine A Curcio; Mark Johnson; Jiahn-Dar Huang; Martin Rudolf
Journal:  Prog Retin Eye Res       Date:  2009-08-19       Impact factor: 21.198

9.  Plasma levels of mannan-binding lectin (MBL)-associated serine proteases (MASPs) and MBL-associated protein in cardio- and cerebrovascular diseases.

Authors:  V Frauenknecht; S Thiel; L Storm; N Meier; M Arnold; J-P Schmid; H Saner; V Schroeder
Journal:  Clin Exp Immunol       Date:  2013-07       Impact factor: 4.330

10.  Anticomplement therapy.

Authors:  Prathit A Kulkarni; Vahid Afshar-Kharghan
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.